Identification of Survival-Related Predictors in Hepatocellular Carcinoma Through Integrated Genomic, Transcriptomic, and Proteomic Analyses

Fangyuan Dong,Qin Yang,Zheng Wu,Xiaona Hu,Dongmei Shi,Min Feng,Jun Li,Lili Zhu,Shu-Heng Jiang,Zhijun Bao

DOI: https://doi.org/10.2139/ssrn.3251497

2018-01-01

Abstract:Patient survival time generally reflects the tumor progression and represents a key clinical parameter. In this study, using copy-number changes, gene mutations, mRNA expression, and reverse phase protein arrays data in hepatocellular carcinoma (HCC) samples with poor and better clinical outcome profiled by The Cancer Genome Atlas (TCGA), we performed comprehensive molecular characterization of prognosisassociated alterations. Among them, several copy number amplifications and deletions can discriminate HCC patients with poor prognosis from those with better prognosis. Mutated DNAH8 showed a worse prognosisspecific pattern and correlated with a reduced disease-free survival in HCC. By integrating RNA sequencing data, we found that HCC samples with poor prognosis are consistently associated with the up-regulation of cell cycle process, such as chromosome separation, DNA replication, cytokinesis, and etc. At the proteomic level, seven proteins were significantly enriched in samples with poor prognosis, including acetylated α-Tubulin, p62-LCK-ligand, ARID1A, MSH6, B-Raf, Cyclin B1, and PEA15. Acetylated α-Tubulin was frequently expressed in HCC tissues and acted as a promising prognostic factor for HCC. Collectively, these alterations lay a foundation for developing relevant therapeutic strategies and improve our knowledge of the pathogenesis of HCC.